Latest big hope against Alzheimer's falls flat in clinical trials

Share this article:
A promising potential treatment for Alzheimer's disease has failed to produce results in the late stages of a clinical trial, according to recent reports.

The drug, Dimebon, had shown immense promise for halting cognitive decline during early testing, according to a report in the New York Times. Originally marketed as an antihistamine in Russia during the 1980s, Dimebon was being developed as an Alzheimer's treatment by San Francisco-based Medivation and global drug giant Pfizer. The results of the first late-stage clinical trial, however, showed that the once-promising drug had virtually no effect after six months of treating mild to moderate Alzheimer's compared with a placebo, the Times reported.

Tests will continue to determine whether Dimebon is effective when coupled with other medications, and the drug is still being tested as a potential treatment for Huntington's disease, the newspaper said. The price of Medivation stock fell by nearly two-thirds to $13.10 Wednesday.


Share this article:

More in News

House leader urges HHS to end settlements meant to cut Medicare backlog

The Department of Health and Human Services may not have had the authority to offer providers special settlements to help clear a huge backlog of Medicare appeals, a leading Congressman said in a recent letter to the agency. Rep. Kevin Brady (R-TX) is urging HHS ...

One-fifth of caregivers take 6 months or longer to choose a senior ...

A significant number of people take six months or longer to choose a senior care or housing option for a loved one, recently released survey results showed.

CMS releases updated Minimum Data Set manual

CMS releases updated Minimum Data Set manual

The Centers for Medicare & Medicaid Services released an updated version of the Minimum Data Set 3.0 Resident Assessment Instrument manual Friday.